Xeris Biopharma: When Liquid Formulations Lead to Profitable Returns
Reading Time: 4 minutes
With patented, water-free formulation technologies, Xeris makes established medications stable at room temperature and immediately applicable via a pre-filled pen, shortening regulatory pathways and significantly reducing development risks. Driven by the growth driver Recorlev, as well as the established specialty products Gvoke and Keveyis, the company achieves an exceptional gross margin of 88% and is already operationally profitable. A patent protection lasting until at least 2040 and the upcoming Phase 3 launch of the weekly thyroid preparation...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.

